---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-046009"
form_type: "8-K"
ticker: "NUWE"
cik: "0001506492"
company_name: "Nuwellis, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:49:03.768851+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nuwellis Q3 revenue $2.4M, net income $2.4M; CMS reimbursement up 297%

## Summary
- Revenue $2.4M, down 2% YoY; pediatrics revenue grew 28% YoY.
- Gross margin 70% vs 57.3% YoY; operating expenses down 30% YoY.
- Net income attributable to common $2.4M ($1.74/share) vs loss $3.4M; includes $3.9M warrant liability benefit.
- CMS increased Aquadex facility fee reimbursement 297% to $1,639/day, effective Jan 1, 2025.
- Cash $1.9M, no debt; $5.1M gross proceeds from November warrant exercise.

## SEC filing metadata
- accession: 0001140361-24-046009
- form_type: 8-K
- ticker: NUWE
- cik: 0001506492
- company_name: Nuwellis, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506492/000114036124046009/0001140361-24-046009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506492/000114036124046009/ef20038370_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-046009
- JSON: https://secwatch.observer/filing/0001140361-24-046009.json
- Plain text: https://secwatch.observer/filing/0001140361-24-046009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.